Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 7 min read

SLU-PP-332 vs Adipotide: what the research compares

A side-by-side look at the published preclinical literature on SLU-PP-332, a pan-ERR agonist, and Adipotide, a vascular-targeted peptidomimetic, covering what each is, what was measured, and where the evidence is thin.

peptides-pro Editorial

What each compound is

SLU-PP-332 is a small-molecule synthetic agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), also referred to as a pan-ERR agonist and widely described in the literature as an exercise mimetic [1][2][4]. It is a chemical probe used to interrogate ERR signalling, and its structural features governing potency, efficacy, selectivity, and drug-like properties have been the subject of a comprehensive structure-activity relationship analysis [2]. The evidence block does not provide a sequence, molecular formula, or molecular weight for SLU-PP-332.

Adipotide is a peptidomimetic compound that targets the vasculature of white adipose tissue. The evidence block does not provide a formal name, sequence, formula, or molecular weight for Adipotide, and no primary studies on Adipotide are included in the evidence supplied for this comparison. The pathway or receptor family central to the SLU-PP-332 work is the estrogen-related receptor (ERR) family of orphan nuclear receptors [1][2][3][5][6].

Research Studies

SLU-PP-332 and in vitro metabolism in human liver fractions

SLU-PP-332 and the related pan-ERR agonist SLU-PP-915 were characterized using liquid chromatography-high resolution tandem mass spectrometry (LC-HRMS/MS), and their in vitro metabolic transformation products were prepared using human liver S9 fractions [1]. The study was framed around the doping potential of pan-ERR agonists, noting that these compounds are being investigated as exercise mimetics because of their ability to trigger human physiological processes similar to those initiated by physical activity [1]. The work is analytical and metabolic in nature; it does not report efficacy endpoints in animals or humans.

SLU-PP-332 and structure-activity relationships at the ERR scaffold

A comprehensive structure-activity relationship (SAR) analysis of the SLU-PP-332 scaffold integrated chemical synthesis, cell-based functional assays, downstream gene-expression profiling, and additional evaluations [2]. The authors describe ERRs as master regulators of mitochondrial metabolism and exercise-responsive transcription, and note that only a limited number of synthetic agonists with suitable potency and drug-like properties have been reported [2]. SLU-PP-332 is described as a well-established exercise mimetic and a widely used chemical probe for ERR activation, but the structural features governing its potency, efficacy, selectivity, and drug-like properties had not been systematically elucidated prior to this work [2].

SLU-PP-332 and ERR activation in myoblasts from inactive women

A pilot study enrolled twenty women undergoing hip arthroplasty for coxarthrosis and divided them into an active group (n = 10) and an inactive group (n = 10) based on self-reported physical activity [3]. The study aimed to evaluate targeting of ERRs in myoblasts isolated from the skeletal muscle of the inactive women by assessing metabolic and expression changes associated with ERR activation [3]. The introduction states that ERRs have been suggested as a potential therapeutic target to counteract muscle decline associated with aging or inactivity, being known to regulate mitochondrial function and cellular respiration by up-regulating key factors in muscle responses to exercise [3]. This is an ex vivo myoblast study, not a clinical trial of SLU-PP-332 in participants.

SLU-PP-332 and doping-control analysis

A separate analytical paper reports on the analysis and identification of in vitro metabolites of SLU-PP-332, describing it as an ERRα/β/γ agonist, for doping-control purposes [4]. That paper notes that exercise mimetics mimic physical activity and may prevent development and progression of chronic metabolic diseases including obesity and Type 2 diabetes, and that the World Anti-Doping Agency prohibits the use of exercise mimetics and metabolic modulators in sports [4]. This is a reference-only item supporting the analytical context of the page.

SLU-PP-332 and pharmacological activation of ERRα/β/γ as an exercise mimetic

A review article addresses pharmacological activation of ERRα/β/γ as an exercise mimetic and its potential therapeutic applications [5]. It states that physical inactivity contributes to the development of chronic diseases and that activation of the orphan nuclear receptors ERRα/β/γ has emerged as a molecular strategy to mimic exercise-induced benefits [5]. The stated aim was to systematically review the current evidence on the physiological, molecular, and clinical dimensions of this approach [5]. This is a reference-only item.

SLU-PP-915 and aerobic exercise capacity

A study of the orally active ERR agonist SLU-PP-915 reports that it enhances aerobic exercise capacity [6]. The paper describes ERRα, ERRβ, and ERRγ as orphan nuclear receptors that regulate genes involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and the Krebs cycle, and states that ERRs are essential for skeletal muscle adaptation to aerobic exercise and represent promising targets for intervention [6]. This is a reference-only item and concerns SLU-PP-915 rather than SLU-PP-332; it is included because the two compounds are discussed together in the SLU-PP-332 literature [1].

SLU-PP-332 and metabolic syndrome in preclinical models

A paper on a synthetic ERR agonist reports that it alleviates metabolic syndrome [7]. The paper notes that physical exercise induces physiologic adaptations and is effective at reducing the risk of premature death from all causes, and that pharmacological exercise mimetics may be effective in the treatment of a range of diseases including obesity and metabolic syndrome [7]. It refers back to the earlier development of SLU-PP-332 as an ERR agonist [7]. This is a reference-only item.

Adipotide and the published record in this evidence set

No primary study, review, or analytical paper on Adipotide is present in the evidence block supplied for this comparison. As a result, no mechanism, tissue, model, or measured endpoint for Adipotide can be reported here without inventing a citation, a number, or a study. The comparison below therefore reflects an asymmetry in the available evidence rather than a judgement about either compound.

Side-by-side summary of what the evidence covers

Dimension SLU-PP-332 Adipotide
Class Synthetic pan-ERR agonist (ERRα/β/γ); exercise mimetic chemical probe [1][2][4] Peptidomimetic (per working description); no class detail in the evidence block
Identifiers in evidence No sequence, formula, or molecular weight given [1][2] No sequence, formula, or molecular weight given
Pathway / receptor family Estrogen-related receptors (ERRα/β/γ) [1][2][3][5][6] Not described in the evidence block
Analytical / metabolism work LC-HRMS/MS characterization and human liver S9 metabolic transformation products [1]; in vitro metabolite identification for doping control [4] None in the evidence block
SAR / medicinal chemistry Comprehensive SAR of the SLU-PP-332 scaffold with cell-based functional assays and gene-expression profiling [2] None in the evidence block
Human-derived tissue work Myoblasts from skeletal muscle of inactive women (n = 10 inactive, n = 10 active) in a pilot study [3] None in the evidence block
Preclinical in vivo work Reported for ERR agonism in metabolic syndrome models [7]; reported for the related agonist SLU-PP-915 in aerobic exercise capacity [6] None in the evidence block
Regulatory / anti-doping context Exercise mimetics and metabolic modulators are prohibited by WADA [4] None in the evidence block

Where the evidence is stronger for one compound

On the material supplied, the published record for SLU-PP-332 is broader and more varied. It spans analytical characterization and in vitro metabolism in human liver fractions [1], a full SAR campaign on the scaffold [2], ex vivo work in myoblasts derived from inactive women [3], metabolite identification for doping-control purposes [4], a systematic review of ERRα/β/γ activation as an exercise mimetic [5], and preclinical work on ERR agonism in metabolic syndrome [7]. The related agonist SLU-PP-915 has its own report on aerobic exercise capacity [6].

For Adipotide, the evidence block contains nothing to compare against. That is not a statement that no literature exists; it is a statement that none was provided here. Any claim about Adipotide's mechanism, tissues, models, or measured endpoints would require a source that this page does not have.

What is simply not known from this evidence

  • No sequence, molecular formula, or molecular weight is given for either compound in the evidence block.
  • No head-to-head study comparing SLU-PP-332 and Adipotide appears in the evidence block.
  • No human clinical trial of SLU-PP-332 is reported in the evidence block; the human-derived work is ex vivo myoblast analysis [3].
  • No pharmacokinetic parameters, half-lives, or exposure values are given for either compound.
  • No safety, tolerability, or adverse-event data are given for either compound.
  • No mechanism, target, or endpoint for Adipotide is available in the evidence block.

If you are reading this for personal health reasons

The materials described here are sold for laboratory research use only. We do not provide dosing or medical guidance, and nothing on this page is a recommendation to use any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp